BioSpace News Archive

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Maurice Zauderer, chief executive officer, will deliver a company presentation at the Oppenheimer 31st Annual Healthcare Conference, which is being held March 16-18, 2021. Presentation details: Date: Tuesday, March 16

Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Allene Diaz to its board of directors.

Ended fourth quarter 2020 with $42.6 million in cash and cash equivalents Aerpio is currently evaluating a range of strategic alternatives focused on maximizing stockholder value from existing clinical and preclinical assets and cash resources Aerpio discontinued RESCUE trial, prior to completion, due to challenges recruiting and monitoring COVID-19 patients in the current pandemic environment

- First-in-human dose-escalation study to evaluate ability of ImmTOR™ to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - - Methylmalonic acidemia (MMA) gene therapy program in collaboration with -

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane”), announced today that Marc Edwards, CEO will be presenting at the Inaugural Emerging Growth Virtual Conference presented by Maxim Group LLC. The conference will take place on March 17 and 18 from 9:00am – 5:00pm EDT

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism – Continued execution on growth strategy to establish a diversified, yet focused, pipeline of development assets leveraging the Company’s expertise and experience

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that two seladelpar presentations will be delivered during the NASH-TAG Conference being held March 11 th – 13 th .

- Positive preclinical data support continued development with strong potential in bone marrow transplant, adoptive cell therapy and gene therapy applications - Potent alpha emitter Actinium-225 targeted to CD45 cells demonstrates positive biodistribution profile and dose-dependent conditioning capabilities

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for poziotinib for the treatment of non-small cell lung cancer (NSCLC)

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Ty Howton as Chief Operating Officer and General Counsel.